|
1.1.Independent predictors of failure of shockwave lithotripsy for ureteral stones employing a second-generation lithotriprer.
D.Delakas,I.Karyotis,G.Daskalopoulos,E.Lianos,E.Mauromanolakis.
J of Endourol 2003, 17: 201-205.
1.2.Membrane androgen binding sites are preferentially expressed in human prostate carcinoma cells.
E.Stathopoulos,C.Dambaki,M.Kampa,P.Theodoropoulos,P.Anezinis,D.Delakas,G.Delides,
E.Castanas.
BMC Clinical Pathology 2003,3: 1-9.
1.3.Symptomatic relief of patients with advanced bladder carcinoma after regional
Intra-arterial chemotherapy.
E.Mantadakis,C.Panagiotidis,D.Delakas,G.Samonis
Anticancer Res 2003, 23(6D): 5143-7.
1.4.Spontaneous perirenal hemorrhage:A 10-year experience at our institution.
G.Daskalopoulos,I.Karyotis,I.Heretis,P.Anezinis,E.Mavromanolakis,D.Delakas
Internat Urol & Nephrol 2004,36: 15-19.
1.5.Electrothermal bipolar coagulation for radical prostatectomies and cystectomies: A preliminary case-controlled study.
G.Daskalopoulos,I.Karyotis,I.Heretis,P.Anezinis,D.Delakas
Internat Urol & Nephrol 2004,36: 181-185.
1.6.Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer.
D.Arvanitis,E.Lianos,N.Soulitzis,D.Delakas,D.Spandidos
Oncology Rep 2004,12:1131-1137.
1.7.Expression analysis of peptide growth factors VEGF, FGF2, TGFB1,EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
N.Soulitzis, I.Karyotis, D.Delakas, D.A. Spandidos
Inter J of Oncol 2006,29: 305-314.
1.8. Μediterranean diet,mononsuturated:saturated`fat ratio and low prostate cancer risk. A myth or a reality?
K.Stamatiou,D.Delakas,F.Sofras
Min Urol & Nefrol 2007,59(1):59-66.
1.9. Pheochromocytoma of the urinary bladder: Report of two cases and review of the literature.
A.Siatelis,C.Konstantinidis,D.Volanis,P.Melidis,V.Leontara,E.Thoma-Tsagli,D.Delakas
Min Urol & Nefrol 2008,60:1-4.
1.10. Post-coital high-flow priapism treated with superselective microcoil embolization
Konstantinidis C,Gekas A,Papatsoris A,KartsaklisP,MourikisD,Delakas D,Sofikitis N
Gaz Med Ital 2010,169:19-21
1.11. Urothelial carcinoma of the sarcomatoid variant in a young patient with spina bifida:a case report and review of the literature
M Nomikos,P Phillipou,C Glava,D Delakas
Cases J 2009,2:9381
1.12. Transrectal Ultrasound-Guided Needle Aspiration of a prostatic Abscess
M Nomikos,I Karyotis,D Volanis,D Delakas
UroToday Inter J 2009,2(6):1944
1.13. Environmental factors and genetic susceptibility promote urinary bladder cancer
D Volanis,T Kadiyska,A Galanis,D Delakas, S Logotheti
Tox Lett 2010,15:193(2):131-7
1.14. Mutational Analysis of the BRAF gene in transitional cell carcinoma of the bladder
I Boulalas,A Zaravinos,D Delakas,D Spandidos
Inter J Biol Mark 2009,24(1):17-21
1.15. Safety of Ultrasound-Guided Transrectal Extended Prostate Biopsy in Patients Receiving Low-dose Aspirin
I Kariotis,P Philippou,D Volanis,E Serafetinides,D Delakas
Inter Br J Urol 2010,36(3):
1.16. Implication of RAF and RKIP Genes in Urinary Bladder Cancer
A Zaravinos,M Chatziioannou,G Lambrou,I Boulalas,D Delakas,D Spandidos
Pathol Oncol Res 2010,
1.17. Plasmacytoid Urothelial Carcinoma of the Bladder: A Rare Malignancy
P Philippou,I Kariotis,D Volanis,A Ploumidis,D Delakas
Urol Inter 2010,
1.18. Prospective Comparative Study of Endoscopic Management OF Bladder Lithiasis:Is Prostate Surgery a Necessary Adjunct?
P Philippou,D Volanis,I Kariotis,E Serafetinides,D Delakas
Urol 2010,
1.19. Statins and prostate cancer:Molecular and clinical aspects
G Papadopoulos,D Delakas,L Nakopoulou,T Kassimatis
Eur JC 2011,
1.20. Activation of RAS Family Genes in Urothelial Carcinoma
I Boulalas,A Zaravinos,I Karyotis,D Delakas,D Spandidos
J Urol 2009,
1.21.Identification of common differentially expressed genes in urinary bladder cancer
A Zaravinos,G Lambrou,I Boulalas,D Delakas,D Spandidos
PLos ONE 2011,6(4):e18135-1-28
1.22.Spotlight on differentially expressed genes in urinary bladder cancer
A Zaravinos,G Lambrou,D Volanis,D Delakas,D Spandidos
PLos ONE 2011,5(6):4,e 18255
1.23. Implication of RAF and RKIP Genes in Urinary Bladder Cancer
A. Zaravinos,M. Chatziioannou,G. Lambrou,I. Boulalas,D. Delakas, D.A. Spandidos
Pathol Oncol Res 2011,17:181-190
1.24. mRNA expression of G(1)-phase cell cycle regulatory molecules in bladder cancer.
Pantazis E,Soulitzis N,Soufla G,Karyotis I,Delakas D,Spandidos DA
J BUON 2011,16(2):323-30
1.25. Expression profile of Rho kinases in urinary bladder cancer
Volanis D, Zaravinos A, Kadiyska T,Delakas D,Spandidos DA
J BUON 2011,16(3):511-521.
1.26. A Computational model for tumor cell membrane tolerance and rigidy limits
G Lambrou,A Zaravinos,M Adamaki,D Delakas,S Vlahopoulos
Proccedings of 10th Inter Workshop on Biomedical Engineering.Kos,5-7 Oct 2011
1.27. Molecular mechanisms in urinary bladder carcinogenesis
Volanis D, Papadopoulos G,Doumas K, Gkialas I,Delakas D
J Buon 2011;16(4):589-601
1.28. Post-esw lithotripsy residual stone fragments:clinical significance and management
O Porfyris,D Delakas
Scand J Urol & Nephrol 2012;early online,1-8
1.29. Expression of miRNAs involved in angiogenesis,tumor cell proliferation,tumorauppressor inhibition,epithelial-mesenchymal transition and activation of metastasis in bladder cancer
A Zaravinos,J Radosicic,G Lambrou,D Volanis,D Delakas,N Stathopoulos,DA Spandidos
J Urol 2012,188(2):615-623
1.30. Role of the angiogenic components, VEGFA,FGF2,OPN and RHOC,in urothelial cell carcinoma of the urinary bladder
Zaravinos A,Volanis D,Lambrou G,Delakas D,Spandidos D
Oncol Rep 2012,28(4):1159-1166
1.31. Association of human herpes,papilloma virus families with bladder cancer
Panagiotakis G,Papadogianni D,Chatziijoannou M,Lasithiotaki I,Delakas D,Spandidos D
Tumour Biol 2012,13:
|
